<DOC>
	<DOCNO>NCT00672581</DOCNO>
	<brief_summary>This study design compare ZD4054 ( Zibotentan ) take , broken remove body subject liver cirrhosis hepatic impairment compare healthy subject similar age , sex weight . As clinical trial , safety tolerability drug evaluate well develop dose recommendation dose ZD4054 ( Zibotentan ) subject vary stage hepatic impairment .</brief_summary>
	<brief_title>Pharmacokinetics , Safety &amp; Tolerability ZD4054 ( Zibotentan ) Subjects With Normal , Mild , Moderate Severe Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Hepatically impaired subject Subjects stable liver cirrhosis hepatic impairment least 3 month prior start study . Healthy volunteer Clinical laboratory test within normal reference range result minor deviation consider Investigator clinically significant In opinion investigator , evidence additional severe uncontrolled systemic disease ( eg , cardiac , renal disease ) evidence significant clinical disorder laboratory find Healthy volunteer History presence hepatic disease know interfere absorption , distribution , metabolism excretion drug Hepatically impaired subject Fluctuating rapidly deteriorate hepatic function indicate widely vary worsen clinical and/or laboratory sign hepatic impairment within screen period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Hepatic Impairment</keyword>
</DOC>